# CJC-1295: What the Safety Record Establishes | Safe CJC-1295 > CJC-1295 is an unapproved long-acting GHRH analog. The verified human PK record, the open safety questions, and the regulatory standing — read as a public dossier, cited to source. A due-diligence dossier on the verified human pharmacokinetics, the open safety questions, and the regulatory standing — every figure logged to its study, every gap left honestly marked. ## What the CJC-1295 record establishes — and where it stops CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is built on the first 29 residues of human GH-releasing factor, hGRF(1-29), with four amino-acid substitutions that block the enzyme that normally clears native GHRH within minutes [2]. In its DAC variant it carries a chemical handle that bonds covalently to circulating serum albumin, which pushes its plasma half-life out to days [1][2]. That long-acting design is the verified part of the story, and it is real: in healthy adults, single subcutaneous doses of 30 or 60 micrograms per kilogram raised mean plasma growth hormone 2- to 10-fold for six days or more and IGF-1 for 9 to 11 days, with an estimated CJC-1295 half-life of 5.8 to 8.1 days [1]. What the record does not contain is the part most pages online assume it does. There is no long-term human safety trial of CJC-1295. The human literature is a handful of short early-phase pharmacokinetic studies in volunteers [1][3], plus a Phase 2 program in HIV-associated visceral obesity that was discontinued [7]. CJC-1295 is not approved for human use by the FDA or any major regulator, and at the 2024 FDA Pharmacy Compounding Advisory Committee it was reviewed and not recommended for the 503A compounding bulks list, with immunogenicity cited among the concerns [8]. It is sold and handled as a research chemical. This site reads that record the way an official dossier reads a public file: a green mark on what the literature genuinely establishes, a gold mark on the open questions, and a red mark on the regulatory standing. The goal is [what the human research shows](/research) without the promotional gloss that usually surrounds the compound. ## CJC-1295 as a synthetic GHRH-analog peptide CJC-1295 is a peptide, not a steroid. It does not act on androgen receptors and it does not supply growth hormone directly. It is a tetrasubstituted hGRF(1-29) analog — a ~30-amino-acid chain that binds the GHRH receptor on the anterior pituitary and prompts the gland to release the body's own growth hormone in its natural pulses [3]. The four substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) exist for one reason: native GHRH is cleaved by the enzyme dipeptidylpeptidase-IV almost immediately, and those changes block that cleavage and stabilize the molecule [2]. That upstream mechanism matters for reading every claim about the compound. Because CJC-1295 works through the pituitary rather than bypassing it, the studies measured growth hormone and IGF-1 — the GH/IGF-1 axis — and nothing else. A notable finding is that the pulsatile pattern of GH release survives the sustained stimulation: in healthy men a single dose raised basal GH roughly 7.5-fold and mean GH by about 46% a week later, yet the frequency and size of the natural GH pulses were unchanged [3]. The peptide raises the floor without flattening the rhythm. ## How the dossier is organized The record splits cleanly into three readings, and each has its own page. The **verified human pharmacokinetics** — half-life, the GH and IGF-1 response, the albumin-conjugation mechanism that makes the DAC form long-acting — live on the research page and in the side-by-side [DAC vs no-DAC (Modified GRF 1-29)](/dac-vs-no-dac) comparison. These are the figures that survived peer review. The **safety reading** — what is documented, what is theoretical, and what is simply absent — is on its own page. The honest summary is short: GH-axis stimulation can cause fluid retention because growth hormone increases renal sodium reabsorption [9]; sustained IGF-1 elevation is the basis for caution drawn from cancer-risk epidemiology [8]; and there is no long-term human safety data to settle either question. See [CJC-1295 side effects and safety](/side-effects) for the full reading, including [the discontinued ConjuChem program](/side-effects). The **regulatory standing** is a fact, not an opinion: unapproved, not on the 503A list, prohibited in sport. Read [is CJC-1295 FDA approved?](/faq) on the FAQ, and the [doses used in the studies](/dosage) for the research-dosing context. The [full reference list](/references) carries every citation with its PMID, DOI, or trial registry number. --- A civic-register dossier on the CJC-1295 record — what the literature establishes marked on the record, the safety gaps left openly blank, and the unapproved status posted plainly; no clinic behind the register and nothing here prescribed or sold.